Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30113% above fair value
$43.24+0.84 (+1.98%)
Close on Nov 11, 2026Market cap $50.39BP/E 72.1Yield –
Teva Pharmaceutical Industries ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Teva Pharmaceutical Industries's ebitda for the twelve months ending Jun 30, 2026 was $2.59B, up 35.2% year over year. For fiscal 2025 it was $3.16B, up 317.9% from the year before. Over ten years it grew -3.8% a year on average. The highest annual figure on record is $5.46B in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.16B | +317.9% |
| FY2024 | Dec 31, 2024 | $756.00M | -52.3% |
| FY2023 | Dec 31, 2023 | $1.59B | – |
| FY2022 | Dec 31, 2022 | -$889.00M | -129.2% |
| FY2021 | Dec 31, 2021 | $3.05B | – |
| FY2020 | Dec 31, 2020 | -$2.02B | -257.5% |
| FY2019 | Dec 31, 2019 | $1.28B | +523.9% |
| FY2018 | Dec 31, 2018 | $205.00M | – |
| FY2017 | Dec 31, 2017 | -$15.37B | -517.9% |
| FY2016 | Dec 31, 2016 | $3.68B | -21.1% |
| FY2015 | Dec 31, 2015 | $4.66B | -14.6% |
| FY2014 | Dec 31, 2014 | $5.46B | +65.9% |
| FY2013 | Dec 31, 2013 | $3.29B | -15.9% |
| FY2012 | Dec 31, 2012 | $3.91B | -6.3% |
| FY2011 | Dec 31, 2011 | $4.18B | -13.8% |
| FY2010 | Dec 31, 2010 | $4.85B | +46.3% |
| FY2009 | Dec 31, 2009 | $3.31B | +102.6% |
| FY2008 | Dec 31, 2008 | $1.64B | -43.5% |
| FY2007 | Dec 31, 2007 | $2.89B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.00M | -98.6% |
| Q1 FY2026 | Mar 31, 2026 | $891.00M | +16.8% |
| Q4 FY2025 | Dec 31, 2025 | $560.00M | +133.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.13B | +443.8% |
| Q2 FY2025 | Jun 30, 2025 | $706.00M | +178.0% |
| Q1 FY2025 | Mar 31, 2025 | $763.00M | +1313.0% |
| Q4 FY2024 | Dec 31, 2024 | $240.00M | -76.5% |
| Q3 FY2024 | Sep 30, 2024 | $208.00M | -66.8% |
| Q2 FY2024 | Jun 30, 2024 | $254.00M | – |
| Q1 FY2024 | Mar 31, 2024 | $54.00M | -81.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.02B | – |
| Q3 FY2023 | Sep 30, 2023 | $627.00M | -15.8% |
| Q2 FY2023 | Jun 30, 2023 | -$354.00M | – |
| Q1 FY2023 | Mar 31, 2023 | $291.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$634.00M | -259.3% |
| Q3 FY2022 | Sep 30, 2022 | $745.00M | -21.7% |
| Q2 FY2022 | Jun 30, 2022 | -$609.00M | -168.7% |
| Q1 FY2022 | Mar 31, 2022 | -$390.00M | -148.1% |
| Q4 FY2021 | Dec 31, 2021 | $398.00M | -50.3% |
| Q3 FY2021 | Sep 30, 2021 | $952.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $887.00M | +59.8% |
| Q1 FY2021 | Mar 31, 2021 | $810.00M | +37.3% |
| Q4 FY2020 | Dec 31, 2020 | $801.00M | +42.0% |
| Q3 FY2020 | Sep 30, 2020 | -$3.96B | -1293.1% |
| Q2 FY2020 | Jun 30, 2020 | $555.00M | – |
| Q1 FY2020 | Mar 31, 2020 | $590.00M | +2.3% |
| Q4 FY2019 | Dec 31, 2019 | $564.00M | – |
| Q3 FY2019 | Sep 30, 2019 | $332.00M | -32.2% |
| Q2 FY2019 | Jun 30, 2019 | -$194.00M | -141.7% |
| Q1 FY2019 | Mar 31, 2019 | $577.00M | -71.6% |
| Q4 FY2018 | Dec 31, 2018 | -$2.78B | – |
| Q3 FY2018 | Sep 30, 2018 | $490.00M | -45.9% |
| Q2 FY2018 | Jun 30, 2018 | $465.00M | – |
| Q1 FY2018 | Mar 31, 2018 | $2.03B | +47.8% |
| Q4 FY2017 | Dec 31, 2017 | -$12.49B | -6504.6% |
| Q3 FY2017 | Sep 30, 2017 | $905.00M | -32.6% |
| Q2 FY2017 | Jun 30, 2017 | -$5.16B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.38B | – |
| Q4 FY2016 | Dec 31, 2016 | $195.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.34B | – |
See a number that looks wrong?